ForPatients
by Roche

Infectious Diseases

A study of long-term effects of fenebrutinib treatment in patients with chronic spontaneous urticaria

A Study to Evaluate the Long-term Safety and Efficacy of Fenebrutinib in Participants Previously Enrolled in a Fenebrutinib Chronic Spontaneous Urticaria (CSU) Study

Trial Status	Trial Runs In	Trial Identifier
Terminated	1 Countries	NCT03693625 2018-002296-17 GS40868

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

This is a Phase II, multicenter, open-label extension (OLE) study to evaluate the long-term safety and efficacy of fenebrutinib in participants with Chronic Spontaneous Urticaria (CSU) who have completed the treatment period in a fenebrutinib CSU parent study. Participants may enroll in this OLE study at any time after completing the treatment period of the parent study. Participants will receive open-label fenebrutinib at a dose of 200 milligram (mg) orally twice a day. Treatment may continue until the end of the study.

Genentech, Inc. Sponsor	**Phase 2** Phase

NCT03693625 2018-002296-17 GS40868
Trial Identifiers

Eligibility Criteria:

Gender	Age	Healthy Volunteers
All	>= 18 Years & <= 75 Years	No

This clinical trial was done to study a new medicine called, “fenebrutinib”, for the treatment of patients with “chronic spontaneous urticaria” or “CSU”. This study was done to find out if the long-term use of fenebrutinib was safe for patients with CSU. Researchers also wanted to find out whether fenebrutinib could provide improvements to CSU symptoms in patients when used long-term. Thirty-one patients took part in this study at nine study centers in the USA.